Lauren Santye, Assistant Editor

Tecentriq provides new option for patients with previously treated metastatic lung cancer.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses the relationship between limited distribution networks and specialty pharmacy.

Top news of the day from across the health care landscape.

Tecentriq is the first anti-PDL1 cancer immunotherapy approved for metastatic non-small cell lung cancer.

A first-of-its-kind study found that medication management programs boost adherence more than 30% in patients with inflammatory bowel disease.

Adalimumab also found to be effective in treating non-infectious uveitis.

T cell subset may play a crucial role in the development of diabetes.

Niraparib significantly improved outcomes of platinum-sensitive recurrent ovarian cancer in landmark trial.

Top news of the day from across the healthcare landscape.

Atezolizumab is a PD-L1 inhibitor that uses the immune system to fight cancer.

Top news of the day from across the health care landscape.

A unique pattern of motion by repair proteins allows them to rapidly scan long DNA and flag repair machinery in condition that can lead to skin cancer.

Nintedanib extends progression-free survival in metastatic colorectal cancer, but failed to extend overall survival.

Oral Sunitinib reduced the likelihood of patients having kidney cancer return.

Study finds that a food-poisoning bacteria increases the growth of gut bacteria linked to Crohn’s disease.

Adjuvant therapy that improves outcomes for kidney cancer patients may finally be an option.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how to address the challenge of access to high cost specialty medications.

After keeping her multiple sclerosis diagnosis a secret for more than a decade, Jamie-Lynn Sigler, teamed up with Biogen’s MS campaign.

Intervention programs may reduce the consumption of sugar, particularly in young males and cervical cancer survivors.

Results from a phase 3 trial demonstrates that nintedanib improved progression-free survival, but not overall survival in colon cancer patients.

A special technique allowed researchers to detail the structure of an enzyme that causes antibiotic resistance.

Top news of the day from across the health care landscape.

Mytesi is the only FDA approved treatment for noninfectious diarrhea in HIV positive patients.

Atezolizumab is a PD-L1 inhibitor designed to use the body’s own immune system to fight cancer.

Atezolizumab demonstrated significant improvement in survival compared with docetaxel in individuals with non-small cell lung cancer.

Premenopausal, overweight women have a decreased risk of breast cancer, while postmenopausal women have an increased risk.

Study highlights care strategies for HIV patients to address the differences in the disease among patients in different age groups.

Baricitinib monotherapy or in combination with methotrexate shows superiority treating rheumatoid arthritis.

Top news of the day from across the health care landscape.

Investigational drug used alone or in combination demonstrated superiority to methotrexate in patients with active rheumatoid arthritis.